Durect corporation to announce fourth quarter and full year 2023 financial results and provide a business update

Cupertino, calif. , march 20, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023 financial results on wednesday, march 27, 2024.
DRRX Ratings Summary
DRRX Quant Ranking